Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma

CK Oh, GP Geba, N Molfino - European Respiratory Review, 2010 - Eur Respiratory Soc
Asthma is a complex, persistent, inflammatory disease characterised by airway hyperresponsiveness
in association with airway inflammation. Studies suggest that regular use of high-…

Molecular and clinical rationale for therapeutic targeting of interleukin‐5 and its receptor

…, R Kolbeck, JM Parker, GP Geba - Clinical & …, 2012 - Wiley Online Library
Interleukin‐5 is a Th2 homodimeric cytokine involved in the differentiation, maturation,
migration, development, survival, trafficking and effector function of blood and local tissue …

[HTML][HTML] REGEN-COV antibody combination and outcomes in outpatients with Covid-19

…, B Kowal, AT DiCioccio, Y Soo, GP Geba… - … England Journal of …, 2021 - Mass Medical Soc
Background In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the
monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of …

[HTML][HTML] Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production

…, RJ Homer, Z Wang, Q Chen, GP Geba… - The Journal of …, 1999 - Am Soc Clin Investig
Interleukin (IL)-13 is a pleiotropic cytokine produced in large quantities by activated CD4 +
Th2 lymphocytes. To define further its potential in vivo effector functions, the Clara cell 10-kDa …

Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice.

H Matsuda, N Watanabe, GP Geba… - International …, 1997 - academic.oup.com
Atopic dermatitis (AD) usually develops in patients with an individual or family history of
allergic diseases, and is characterized by chronic relapsing inflammation seen especially in …

Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness

UA Temann, GP Geba, JA Rankin… - The Journal of …, 1998 - rupress.org
GP Geba was supported by NIH grants HL-03229 and HL-56389. JA Rankin was supported
by NIH grant HL-54450 and by the Veterans Administration. RA Flavell is an investigator of …

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

…, D She, C Kell, RD May, GP Geba… - European …, 2013 - Eur Respiratory Soc
Pre-clinical data demonstrate a pivotal role for interleukin (IL)-13 in the development and
maintenance of asthma. This study assessed the effects of tralokinumab, an investigational …

Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti–IL-5 receptor α antibody, in a phase I study of subjects with mild asthma

…, M Koike, GL Spitalny, PA Kiener, GP Geba… - Journal of Allergy and …, 2010 - Elsevier
BACKGROUND: Increased eosinophil levels have been linked to airway inflammation and
asthma exacerbations. IL-5 is responsible for eosinophil differentiation, proliferation, and …

Treatment of chronic autoimmune urticaria with omalizumab

AP Kaplan, K Joseph, RJ Maykut, GP Geba… - Journal of Allergy and …, 2008 - Elsevier
BACKGROUND: Approximately 45% of patients with chronic urticaria have an IgG autoantibody
directed to the α-subunit of the high-affinity IgE receptor (chronic autoimmune urticaria, …

Phenotypic and physiologic characterization of transgenic mice expressing interleukin 4 in the lung: lymphocytic and eosinophilic inflammation without airway …

JA Rankin, DE Picarella, GP Geba… - Proceedings of the …, 1996 - National Acad Sciences
To investigate the contribution of interleukin-4 (IL-4) to airway inflammation in vivo and to
explore directly its relationship to airway reactivity, we created transgenic mice in which the …